Latest California Healthline Stories
Ten Doctors on FDA Panel Reviewing Abbott Heart Device Had Financial Ties With Company
Most of the doctors the FDA tapped to advise it on an Abbott medical device had financial ties to the company. The FDA didn’t disclose the payments.
Biden Is Right About $35 Insulin Cap but Exaggerates Prior Costs for Medicare Enrollees
Most Medicare enrollees likely were not paying a monthly average of $400 — as President Joe Biden stated — before the insulin cap took effect. However, because costs and other factors result in widely varying prices, some Medicare enrollees might have paid that much in a given month.
KFF Health News' 'What the Health?': The Supreme Court and the Abortion Pill
The Supreme Court this week heard its first abortion case since overturning Roe v. Wade in 2022, about an appeals court ruling that would dramatically restrict the availability of the abortion pill mifepristone. But while it seems likely that this case could be dismissed on a technicality, abortion opponents have more challenges in the pipeline. Meanwhile, health issues are heating up on the campaign trail, as Republicans continue to take aim at Medicare, Medicaid, and the Affordable Care Act — all things Democrats are delighted to defend. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Lauren Weber of The Washington Post join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KFF Health News’ Tony Leys, who wrote a KFF Health News-NPR “Bill of the Month” feature about Medicare and a very expensive air-ambulance ride. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
At Stake in Mifepristone Case: Abortion, FDA’s Authority, and Return to 1873 Obscenity Law
The end goal for a conservative Christian group’s mifepristone case before the Supreme Court: a de facto nationwide abortion ban.
KFF Health News' 'What the Health?': The ACA Turns 14
Saturday marks the 14th anniversary of the still somewhat embattled Affordable Care Act. Health and Human Services Secretary Xavier Becerra joins host Julie Rovner to discuss the accomplishments of the health law — and the challenges it still faces. Also this week, Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Mary Agnes Carey of KFF Health News join Rovner to discuss what should be the final funding bill for HHS for fiscal 2024, next week’s Supreme Court oral arguments in a case challenging abortion medication, and more. Plus, for “extra credit,” the panelists suggest health policy stories they read this week they think you should read, too.
Watch: Many Americans Are Unaware of HIV Prevention Medication
Some Americans mistakenly believe medication to prevent HIV transmission through sex is just for certain groups such as gay men, but anyone who’s at risk for contracting HIV through sex could benefit.
When Copay Assistance Backfires on Patients
Drugmakers offer copay assistance programs to patients, but insurers are tapping into those funds, not counting the amounts toward patient deductibles. That leads to unexpected charges. But the practice is under growing scrutiny.
KFF Health News' 'What the Health?': Maybe It’s a Health Care Election After All
Health care wasn’t expected to be a major theme for this year’s elections. But as President Joe Biden and former President Donald Trump secured their respective party nominations this week, the future of both Medicare and the Affordable Care Act appears to be up for debate. Meanwhile, the cyberattack of the UnitedHealth Group subsidiary Change Healthcare continues to do damage to the companies’ finances with no quick end in sight. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News, and Joanne Kenen of Johns Hopkins University and Politico Magazine join KFF Health News’ Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kelly Henning of Bloomberg Philanthropies about a new, four-part documentary series on the history of public health, “The Invisible Shield.” Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too.
Why Covid Patients Who Could Most Benefit From Paxlovid Still Aren’t Getting It
Price worries, bureaucratic obstacles, and “I’m-over-covid-itis” slow uptake of a drug that’s complicated to take but often effective.
A New $16,000 Postpartum Depression Drug Is Here. How Will Insurers Handle It?
A pill form of an effective drug for postpartum depression hit the market in December, but most insurers do not yet have a policy on when or whether they will pay for it. The hurdles to obtain its predecessor medication have advocates worried.